NB

Neochem Bio

Q4 FY26

Neochem Bio Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹111

Market cap₹191 Cr

P/E15.3

Updated16 Oct 2026

Read4 min read

What the Q4 FY26 call signalled

2 of 4 strong

RevenueGood growth

MarginMargins steady

CapexNo capex planned

Order bookOrder book rising

The short version

Neochem targets around 2%-3% R&D spend of revenue to drive innovation and new product commercialization. Neochem aims to maintain R&D spends around 2-3% of revenue to drive innovation and commercialize new products, supporting long-term growth.

From Neochem Bio's Q4 FY26 earnings-call transcript · updated 16 Oct 2026.

Revenue & Sales Performance

Good growth

Neochem targets around 2%-3% R&D spend of revenue to drive innovation and new product commercialization.
Focus on textiles, home and personal care (HPC), and paints and coatings as key growth industries; HPC and paints could become comparable to textiles in 3-7 years.
Export revenue targeted to grow from 5% to around 30%-35% over the next few years, focusing on South Asia, Southeast Asia, Africa, and plans for North America.
Capacity utilization improved from ~35% in FY24 to 53% in FY26, with significant headroom (47%) for growth without major capex.
Volume growth for FY26 was 26% YoY; management believes the current lower base and market consolidation enable sustaining ~30% volume growth for next 2-3 years.

2 more points from Neochem Bio's call on revenue

Pro opens every point from 15K+ earnings calls

Profitability & Margins

Neochem aims to maintain R&D spends around 2-3% of revenue to drive innovation and commercialize new products, supporting long-term growth.
Focused on strong growth in textiles, with significant headroom, and rapid scaling in home & personal care and paints & coatings segments expected to become comparable to textiles in 3-7 years.
Expects export revenue to grow from current ~5% to around 30-35% of total revenue, targeting South Asia, Southeast Asia, Africa, and exploring North America and Europe.
Capacity utilization improved from ~35% in FY24 to 53% in FY26, with 47% remaining unused capacity, enabling scalable growth without major capex in short term.
EBITDA margin improved by 321 bps to 20.4% in FY26, with PAT margin at 10.6%, targeting sustainable margins of 18-20% EBITDA and 11-12% PAT as scale increases.

2 more points from Neochem Bio's call on margins

Pro opens every point from 15K+ earnings calls

See what Neochem Bio said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

No capex planned

No major planned capex over the next 1.5 to 2 years is anticipated.
Business being formulation-driven may require some additions like equipment or lab testing instruments, which are ongoing and not significant.
Existing Moraiya facility has 47% capacity headroom, allowing significant growth without immediate manufacturing capex.

2 more points from Neochem Bio's call on capex

Pro opens every point from 15K+ earnings calls

Fundraising & Capital Structure

No major planned capital expenditure (capex) is expected over the next 1.5 to 2 years, reducing the immediate need for large fundraising.
Current short-term borrowings (INR17.1 crores) are primarily for working capital; finance costs remain stable with de-leveraging efforts in place.
The company has significantly reduced long-term borrowings from INR14.3 crores in FY25 to INR0.7 crores in FY26, improving financial flexibility.
No mention of planned new debt or equity fundraising in the short term.

2 more points from Neochem Bio's call on fundraising

Pro opens every point from 15K+ earnings calls

See what Neochem Bio said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Order book rising

The transcript from the pages provided does not explicitly mention details about the current or expected order book or pending orders for Neochem Bio Solutions Limited. However, some relevant insights can be inferred: - The company demonstrated strong demand with 32% year-on-year growth in revenue for FY26. - Quarter 4 contributed over 32% of annual revenue, reflecting strong sales momentum. - There is a robust product pipeline with new product launches such as the FabBrite series and Ampinol LDT. - The focus on proprietary branded products is increasing, with more than 80% of the business from own-brand sales.

2 more points from Neochem Bio's call on order book

Pro opens every point from 15K+ earnings calls

What Neochem Bio Solutions Ltd's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

Vishnu Chemicals Ltd (Q4 FY26)
Q4 FY26 Operating Revenues: ₹450.3 crore, up 14.7% YoY from ₹392.6 crore in Q4 FY25 (Page 5). Key investor presentation takeaways from Vishnu Chemicals Ltd's Q4
SPEB Adhesives Ltd (Q4 FY26)
The company plans to double its manufacturing capacity, currently at about 80% utilization, with new capacity ramp-up phased over time. Key concall takeaways…
Chemfab Alka. (Q4 FY26)
Chlor Alkali segment: ₹55.63 crore (down 1.21% YoY from ₹56.31 crore) . Key concall takeaways from Chemfab Alkalis Ltd's Q4 FY26 earnings call — and how it…
Sudarshan Pharma Industries Ltd (Q4 FY26)
Revenue from Operations for Q4 March 2026: ₹220.92 Cr (Page 41) . Key concall takeaways from Sudarshan Pharma Industries Ltd's Q4 FY26 earnings call — and how…

Compare:vs Solar Industries vs SRF Ltd vs Linde India Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Neochem Bio and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Neochem Bio Q4 FY26 results?

Neochem targets around 2%-3% R&D spend of revenue to drive innovation and new product commercialization. Neochem aims to maintain R&D spends around 2-3% of revenue to drive innovation and commercialize new products, supporting long-term growth.

What is Neochem Bio share price analysis?

Neochem Bio currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 15.3 with a market cap of ₹191 Cr. Investors should review the full earnings analysis for detailed insights.

Is Neochem Bio planning capital expenditure?

No major planned capex over the next 1.5 to 2 years is anticipated.

Keep Neochem Bio on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.